^

Health

Orgalutran

, medical expert
Last reviewed: 23.04.2024
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Orgalutran helps reduce gonadotropin levels. The drug is used in treatment programs for infertility - to prevent a premature increase in the values of lyutropin during controlled ovulation.

It is necessary to use the medication to stimulate the process of superovulation for a short time, while the follicles are at the final stage of growth, when there is a probability of a premature release of this hormone (this often happens on the 6th day of stimulation). This effect is reversible, recovery of pituitary activity occurs after 2 days.

trusted-source[1]

Indications Orgalutrana

It is used in the case of female infertility - during ART procedures, to prevent premature onset of ovulation.

trusted-source[2], [3]

Release form

The release of the drug component is in the form of a solution for s / c injections, inside a syringe with a volume of 0.5 ml.

trusted-source[4], [5]

Pharmacodynamics

Orgalutran is a gonadorelin antagonist that slows the release of gonadotropins through the pituitary gland.

The therapeutic effect develops when blocking the action of the pituitary endings of GnRH. The drug is strongly synthesized with these endings, providing an immediate effect - there is a significant decrease in the rate of gonadotropins (mainly LH). The intensity of the depression of gonadotropins is determined by the size of the dosage.

trusted-source[6], [7]

Pharmacokinetics

After 1-2 hours after the use of the drug, a blood index Cmax is recorded. The level of bioavailability is 91%. When reusing Css values are noted after 2-3 days. There is an inverse relationship between serum drug values and woman's weight.

Exchange processes are made with the formation of peptide elements. The term half-life is about 13 hours.

Excretion is carried out by the intestines (75%), as well as the kidneys (22%). In connection with the accelerated elimination of drugs from the body, the indicators of gonadotropins are restored fairly quickly. Thanks to this effect of Orgalutran, it is possible to control the activity of the pituitary gland - in time oppressing and restoring it.

trusted-source[8], [9]

Dosing and administration

The drug is used daily - through s / c injections into the thigh area. It is necessary to carry out injections at the same time, while constantly changing the area of the injection. The drug has a high rate of reversibility of exposure, which is why the intervals between the injections should be a maximum of 30 hours. In the case of use in the morning, the drug should be administered on the day when hCG is used, and in the case of evening injections, the last injection is given in the evening, before the day of hCG. When you skip the procedure, you can not enter the 2nd portion.

The control of ovulation stimulation should be started with an FSH substance (for example, purgona) on the 2-3rd day of the course, and Orgalutran in a 0.25 mg dose is used on the 6th day of the FSH administration. In the case of an enhanced response to the stimulation process, the administration of the drug is made earlier, and with slow follicular growth, later than the 6th day.

It is forbidden to use liquid having an opaque shape or containing impurities. Before performing the procedure, you need to wash your hands, and also treat the site of the injection with a cotton swab soaked in alcohol.

trusted-source[11], [12]

Use Orgalutrana during pregnancy

It is forbidden to use the drug during pregnancy.

Contraindications

The main contraindications:

  • severe intolerance to the components of drugs;
  • postmenopause;
  • kidney failure;
  • breastfeeding period.

trusted-source[10]

Side effects Orgalutrana

Common side effects develop only occasionally: headaches, nausea, epidermal eruptions, malaise, dyspnea, dizziness, systemic weakness and pain in the abdominal area.

OHS sometimes develops, with an increase in the size of the ovaries, pain in the lower abdomen, oliguria, diarrhea, breathing problems and weight gain.

Local symptoms include redness, swelling and itching in the area of the injection.

trusted-source

Overdose

In case of drug intoxication, a prolongation of the period of its influence occurs. It is necessary to abolish the use of drugs for a while, and the doctor should take a decision on further actions.

trusted-source[13], [14], [15]

Storage conditions

Organalutran is required to be kept at temperature indices not exceeding the mark of 30 ° C.

Shelf life

Organalutran can be used within a 24-month term from the time the therapeutic substance is produced.

Application for children

The drug is not prescribed in pediatrics.

trusted-source[16], [17]

Analogs

An analogue of the drug is the substance Cetrotid.

trusted-source[18], [19], [20], [21], [22]

Attention!

To simplify the perception of information, this instruction for use of the drug "Orgalutran" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.